Skip to main content
2274 search results for:

Lenvatinib 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 01-05-2024 | Lenvatinib | News

    Lenvatinib

    Lack of efficacy
  2. 01-05-2024 | Lenvatinib | News

    Lenvatinib/pembrolizumab

    Prothrombotic milieu
  3. 01-05-2024 | Lenvatinib | News

    Lenvatinib

    Various toxicities and lack of efficacy
  4. Open Access 01-12-2024 | Lenvatinib | OriginalPaper

    HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study

    Hepatocellular carcinoma (HCC) is a prevalent malignancy, ranking as the sixth most frequently diagnosed cancer and the third leading cause of cancer-related mortality globally [ 1 , 2 ]. The burden of HCC is particularly high in Asia, where …

  5. 01-04-2024 | Lenvatinib | News

    Lenvatinib

    Lack of drug effect
  6. 01-04-2024 | Lenvatinib | News

    Lenvatinib

    Anorexia and general fatigue
  7. 01-04-2024 | Lenvatinib | News

    Lenvatinib

    Rectal ulcer
  8. 01-04-2024 | Sorafenib | News

    Lenvatinib/Sorafenib

    Hand‑foot skin reaction, hematotoxicity and lack of efficacy
  9. 01-04-2024 | Lenvatinib | News

    Iodine-131/lenvatinib

    Lack of efficacy
  10. 01-04-2024 | Lenvatinib | News

    Lenvatinib

    Cardiomyopathy
  11. 01-04-2024 | Lenvatinib | News

    Lenvatinib

    Hypertensive crises
  12. 01-04-2024 | Vulgar Psoriasis | News

    Lenvatinib/pembrolizumab

    Lack of efficacy
  13. 01-03-2024 | Lenvatinib | News

    Lenvatinib/pembrolizumab

    Various toxicities
  14. Open Access 01-12-2024 | Lenvatinib | OriginalPaper

    Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion

    Primary liver cancer is the sixth highest morbidity cancer in the world and the third highest cause of cancer mortality. China has the largest population of primary liver cancer. An estimated 9.5 and 8.7 new cases and deaths of primary liver …

  15. 01-03-2024 | Lenvatinib | News

    Lenvatinib/sorafenib

    Various toxicites
  16. 08-05-2024 | Online First

    Is the TAE score a promising prognostic predictor for unresectable hepatocellular carcinoma treated with TACE plus lenvatinib with PD‑1 inhibitors? Further validation should be performed

  17. 01-03-2024 | Lenvatinib | News

    Lenvatinib

    Lack of drug effect
  18. 26-04-2024 | Lenvatinib | Online First

    Clinical efficacy of lenvatinib, trans-arterial chemoembolization, and PD-1/L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis

    Primary liver cancer is currently the fourth most common malignant tumor and the second leading cause of cancer-related deaths in China, posing a significant threat to the lives and health of the Chinese population [ 1 ]. This paper uses the …

  19. Open Access 01-12-2024 | Lenvatinib | OriginalPaper

    Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial

    Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer-related deaths worldwide [ 1 ]. The majority of HCC (approximately 72%) are diagnosed in Asia, with hepatitis B virus (HBV) infection being the …

  20. Open Access 01-12-2024 | Lenvatinib | OriginalPaper

    Repression of LSD1/KDM1A activity improves the response of liver cancer cells to the lenvatinib

    Liver cancer is a major cause of cancer-associated death in the world [ 1 ]. Primary liver cancer (PLC) has three main histological subtypes-hepatocellular carcinoma (accounting for approximate 90% of liver cancers), intrahepatic cholangiocarcinoma …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.